Adaptive Biotechnologies has the Profitability Rank of 2. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Adaptive Biotechnologies's Operating Margin % for the quarter that ended in Dec. 2023 was -99.68%. As of today, Adaptive Biotechnologies's Piotroski F-Score is 1.
Competitive Comparison
For the Biotechnology subindustry, Adaptive Biotechnologies's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies Profitability Rank Distribution
For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's Profitability Rank falls into.
Adaptive Biotechnologies Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Adaptive Biotechnologies has the Profitability Rank of 2. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Adaptive Biotechnologies's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 1 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Adaptive Biotechnologies has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Warning Sign:
Adaptive Biotechnologies Corp operating margin has been in a 5-year decline. The average rate of decline per year is -5.1%.
4. Consistency of the profitability
5. Predictability Rank
Adaptive Biotechnologies (Adaptive Biotechnologies) Business Description
Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").
Executives
| Kyle Piskel |
officer: Principal Accounting Officer |
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
| Nitin Sood |
officer: Chief Commercial Officer, MRD |
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
| Tycho Peterson |
officer: Chief Financial Officer |
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109 |
| R Mark Adams |
officer: Chief Operating Officer |
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
| Michelle Renee Griffin |
director |
19723 NE 65TH LANE, KIRKLAND WA 98033 |
| Stacy L Taylor |
officer: SVP and General Counsel |
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102 |
| Leslie Trigg |
director |
C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112 |
| Kevin T Conroy |
director |
5505 ENDEAVOR LANE, MADISON WI 53719 |
| Robert Hershberg |
director |
3005 FIRST AVENUE, SEATTLE WA 98121 |
| Peter M Neupert |
director |
13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005 |
| Sharon Benzeno |
officer: Chief Commercial Ofc Imm Med |
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
| Harlan S Robins |
officer: Chief Scientific Officer |
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
| Francis Lo |
officer: Chief People Officer |
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
| Michael J Pellini |
director |
222 DUTTON MILL RD, WILLISTOWN PA 19380 |
| Chad M Robins |
director, officer: CEO and Chairman |
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADPT has been successfully added to your